These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

294 related articles for article (PubMed ID: 32468091)

  • 21. Intravesical bacillus Calmette-Guerin immunotherapy after previous prostate radiotherapy for high-grade non-muscle-invasive bladder cancer.
    Rao MV; Ellimoottil C; Sondej T; Flanigan RC; Quek ML
    Urol Oncol; 2013 Aug; 31(6):857-61. PubMed ID: 21868262
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Female gender and carcinoma in situ in the prostatic urethra are prognostic factors for recurrence, progression, and disease-specific mortality in T1G3 bladder cancer patients treated with bacillus Calmette-Guérin.
    Palou J; Sylvester RJ; Faba OR; Parada R; Peña JA; Algaba F; Villavicencio H
    Eur Urol; 2012 Jul; 62(1):118-25. PubMed ID: 22101115
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Bladder-preserving strategies for Bacillus Calmette-Guérin unresponsive non-muscle invasive bladder cancer; where are we and what will be expected?
    Sari Motlagh R; Pradere B; Mori K; Miura N; Abufaraj M; Shariat SF
    Curr Opin Urol; 2020 Jul; 30(4):584-593. PubMed ID: 32304379
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Patterns of recurrence and outcomes following induction bacillus Calmette-Guerin for high risk Ta, T1 bladder cancer.
    Lerner SP; Tangen CM; Sucharew H; Wood D; Crawford ED
    J Urol; 2007 May; 177(5):1727-31. PubMed ID: 17437798
    [TBL] [Abstract][Full Text] [Related]  

  • 25. EORTC Nomograms and Risk Groups for Predicting Recurrence, Progression, and Disease-specific and Overall Survival in Non-Muscle-invasive Stage Ta-T1 Urothelial Bladder Cancer Patients Treated with 1-3 Years of Maintenance Bacillus Calmette-Guérin.
    Cambier S; Sylvester RJ; Collette L; Gontero P; Brausi MA; van Andel G; Kirkels WJ; Silva FC; Oosterlinck W; Prescott S; Kirkali Z; Powell PH; de Reijke TM; Turkeri L; Collette S; Oddens J
    Eur Urol; 2016 Jan; 69(1):60-9. PubMed ID: 26210894
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Anti-inflammatory use may not negatively impact oncologic outcomes following intravesical BCG for high-grade non-muscle-invasive bladder cancer.
    Singla N; Haddad AQ; Passoni NM; Meissner M; Lotan Y
    World J Urol; 2017 Jan; 35(1):105-111. PubMed ID: 27194044
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Required efficacy for novel therapies in BCG-unresponsive non-muscle invasive bladder cancer: Do current recommendations really reflect clinically meaningful outcomes?
    Wettstein MS; Naimark D; Hermanns T; Herrera-Caceres JO; Ahmad A; Jewett MAS; Kulkarni GS
    Cancer Med; 2020 May; 9(10):3287-3296. PubMed ID: 32163677
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Immunotherapy in Bacillus Calmette-Guerin (BCG) unresponsive nonmuscle invasive bladder cancer.
    Hugar LA; Gilbert SM; Sexton WJ; Kamat AM; Li R
    Curr Opin Urol; 2021 Mar; 31(2):160-169. PubMed ID: 33394766
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Oncological outcomes of a single but extensive transurethral resection followed by appropriate intra-vesical instillation therapy for newly diagnosed non-muscle-invasive bladder cancer.
    Koie T; Ohyama C; Hosogoe S; Yamamoto H; Imai A; Hatakeyama S; Yoneyama T; Hashimoto Y; Yoneyama T; Tobisawa Y; Mori K
    Int Urol Nephrol; 2015 Sep; 47(9):1509-14. PubMed ID: 26149637
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Intravesical Bacillus Calmette Guerin Combined with a Cancer Vaccine Increases Local T-Cell Responses in Non-muscle-Invasive Bladder Cancer Patients.
    Derré L; Cesson V; Lucca I; Cerantola Y; Valerio M; Fritschi U; Vlamopoulos Y; Burruni R; Legris AS; Dartiguenave F; Gharbi D; Martin V; Vaucher L; Speiser DE; Romero P; Jichlinski P; Nardelli-Haefliger D
    Clin Cancer Res; 2017 Feb; 23(3):717-725. PubMed ID: 27521445
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Bacillus Calmette-Guérin-unresponsive non-muscle-invasive bladder cancer: Its definition and future therapeutic strategies.
    Kikuchi E; Hayakawa N; Fukumoto K; Shigeta K; Matsumoto K
    Int J Urol; 2020 Feb; 27(2):108-116. PubMed ID: 31793703
    [TBL] [Abstract][Full Text] [Related]  

  • 32. What to do during Bacillus Calmette-Guérin shortage? Valid strategies based on evidence.
    Abufaraj M; Mostafid H; Shariat SF; Babjuk M
    Curr Opin Urol; 2018 Nov; 28(6):570-576. PubMed ID: 30138122
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Management of high-risk non-muscle invasive bladder cancer.
    Brausi M; Olaru V
    Minerva Urol Nefrol; 2012 Dec; 64(4):255-60. PubMed ID: 23288212
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Is intravesical Bacillus Calmette-Guérin therapy superior to chemotherapy for intermediate-risk non-muscle-invasive bladder cancer? An ongoing debate.
    Han KS; You D; Jeong IG; Kwon T; Hong B; Hong JH; Ahn H; Ahn TY; Kim CS
    J Korean Med Sci; 2015 Mar; 30(3):252-8. PubMed ID: 25729246
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Intravesical bacillus Calmette-Guérin instillation in non-muscle-invasive bladder cancer: A review.
    Saluja M; Gilling P
    Int J Urol; 2018 Jan; 25(1):18-24. PubMed ID: 28741703
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Intravesical therapy for bladder cancer.
    Williams SK; Hoenig DM; Ghavamian R; Soloway M
    Expert Opin Pharmacother; 2010 Apr; 11(6):947-58. PubMed ID: 20205607
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy and safety of photodynamic therapy for recurrent, high grade nonmuscle invasive bladder cancer refractory or intolerant to bacille Calmette-Guérin immunotherapy.
    Lee JY; Diaz RR; Cho KS; Lim MS; Chung JS; Kim WT; Ham WS; Choi YD
    J Urol; 2013 Oct; 190(4):1192-9. PubMed ID: 23648222
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Definitive BCG immunotherapy versus radical cystectomy in intermediate or high-risk nonmuscle invasive bladder cancer patients: A retrospective study.
    Jian X; Shen M; Liao G
    Medicine (Baltimore); 2019 Sep; 98(36):e16873. PubMed ID: 31490371
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Salvage therapeutic strategies for bacillus Calmette-Guerin failure.
    Hassler MR; Shariat SF; Soria F
    Curr Opin Urol; 2019 May; 29(3):239-246. PubMed ID: 30762670
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Intermediate- and high-risk nonmuscle invasive bladder cancer: Where do we stand?
    Basile G; Pederzoli F; Bandini M; Raggi D; Gallina A; Salonia A; Briganti A; Montorsi F; Spiess PE; Necchi A
    Urol Oncol; 2021 Oct; 39(10):631-641. PubMed ID: 33766463
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.